Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Compass Therapeutics (CMPX) Depreciation & Amortization (CF) (2023 - 2025)

Compass Therapeutics (CMPX) has disclosed Depreciation & Amortization (CF) for 3 consecutive years, with $17000.0 as the latest value for Q4 2025.

  • Quarterly Depreciation & Amortization (CF) fell 87.86% to $17000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $276000.0 through Dec 2025, down 53.14% year-over-year, with the annual reading at $276000.0 for FY2025, 53.14% down from the prior year.
  • Depreciation & Amortization (CF) hit $17000.0 in Q4 2025 for Compass Therapeutics, down from $19000.0 in the prior quarter.
  • In the past five years, Depreciation & Amortization (CF) ranged from a high of $194000.0 in Q1 2023 to a low of $17000.0 in Q4 2025.
  • Historically, Depreciation & Amortization (CF) has averaged $130333.3 across 3 years, with a median of $147500.0 in 2024.
  • Biggest YoY gain for Depreciation & Amortization (CF) was 9.09% in 2025; the steepest drop was 87.86% in 2025.
  • Year by year, Depreciation & Amortization (CF) stood at $161000.0 in 2023, then dropped by 13.04% to $140000.0 in 2024, then plummeted by 87.86% to $17000.0 in 2025.
  • Business Quant data shows Depreciation & Amortization (CF) for CMPX at $17000.0 in Q4 2025, $19000.0 in Q3 2025, and $100000.0 in Q2 2025.